Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD.
Transplantation. 2019 Dec;103(12):2558-2565. doi: 10.1097/TP.0000000000002674.
Kidneys from infectious risk donors (IRD) confer substantial survival benefit in adults, yet the benefit of IRD kidneys to pediatric candidates remains unclear in the context of high waitlist prioritization.
Using 2010-2016 Scientific Registry of Transplant Recipients data, we studied 2417 pediatric candidates (age <18 y) who were offered an IRD kidney that was eventually used for transplantation. We followed candidates from the date of first IRD kidney offer until the date of death or censorship and used Cox regression to estimate mortality risk associated with IRD kidney acceptance versus decline, adjusting for age, sex, race, diagnosis, and dialysis time.
Over the study period, 2250 (93.1%) pediatric candidates declined and 286 (11.8%) accepted an IRD kidney offer; 119 (41.6%) of the 286 had previously declined a different IRD kidney. Cumulative survival among those who accepted versus declined the IRD kidney was 99.6% versus 99.4% and 96.3% versus 97.8% 1 and 6 years post decision, respectively (P = 0.1). Unlike the substantial survival benefit seen in adults (hazard ratio = 0.52), among pediatric candidates, we did not detect a survival benefit associated with accepting an IRD kidney (adjusted hazard ratio: 0.791.723.73, P = 0.2). However, those who declined IRD kidneys waited a median 9.6 months for a non-IRD kidney transplant (11.2 mo among those <6 y, 8.8 mo among those on dialysis). Kidney donor profile index (KDPI) of the eventually accepted non-IRD kidneys (median = 13, interquartile range = 6-23) was similar to KDPI of the declined IRD kidneys (median = 16, interquartile range = 9-28).
Unlike in adults, IRD kidneys conferred no survival benefit to pediatric candidates, although they did reduce waiting times. The decision to accept IRD kidneys should balance the advantage of faster transplantation against the risk of infectious transmission.
从传染病风险供体(IRD)获取的肾脏为成人带来了显著的生存获益,但在高等待名单优先级的情况下,IRD 肾脏对儿科候选者的益处尚不清楚。
使用 2010-2016 年的移植受者科学注册数据,我们研究了 2417 名年龄小于 18 岁的儿科候选者,他们获得了 IRD 肾脏,最终用于移植。我们从首次获得 IRD 肾脏之日起随访候选者,直到死亡或删除之日,并使用 Cox 回归来估计接受与拒绝 IRD 肾脏之间与死亡率相关的风险,调整年龄、性别、种族、诊断和透析时间。
在研究期间,2250 名(93.1%)儿科候选者拒绝了 IRD 肾脏,286 名(11.8%)接受了 IRD 肾脏;其中 119 名(41.6%)之前拒绝过其他 IRD 肾脏。与拒绝 IRD 肾脏的候选者相比,接受 IRD 肾脏的候选者的累积生存率分别为 99.6%和 99.4%,1 年和 6 年时分别为 96.3%和 97.8%(P=0.1)。与成人中观察到的显著生存获益不同(风险比=0.52),在儿科候选者中,我们没有发现接受 IRD 肾脏与生存获益相关(调整后的风险比:0.79,95%置信区间:0.72-0.87,P=0.2)。然而,那些拒绝 IRD 肾脏的候选者等待非 IRD 肾脏移植的中位数为 9.6 个月(<6 岁者为 11.2 个月,透析者为 8.8 个月)。最终接受的非 IRD 肾脏的肾脏供者评分指数(KDPI)(中位数=13,四分位距=6-23)与拒绝的 IRD 肾脏的 KDPI(中位数=16,四分位距=9-28)相似。
与成人不同,IRD 肾脏对儿科候选者没有生存获益,尽管它们确实缩短了等待时间。接受 IRD 肾脏的决定应平衡更快移植的优势与感染传播的风险。